These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16830258)

  • 1. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer.
    Sullivan PW; Nelson JB; Mulani PM; Sleep D
    Qual Life Res; 2006 Oct; 15(8):1297-306. PubMed ID: 16830258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer.
    Sullivan PW; Mulani PM; Fishman M; Sleep D
    Qual Life Res; 2007 May; 16(4):571-5. PubMed ID: 17294287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group.
    Collette L; van Andel G; Bottomley A; Oosterhof GO; Albrecht W; de Reijke TM; Fossà SD
    J Clin Oncol; 2004 Oct; 22(19):3877-85. PubMed ID: 15459209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer.
    Cella D; Nichol MB; Eton D; Nelson JB; Mulani P
    Value Health; 2009; 12(1):124-9. PubMed ID: 18647260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline FACT-G score is a predictor of survival for advanced lung cancer.
    Dharma-Wardene M; Au HJ; Hanson J; Dupere D; Hewitt J; Feeny D
    Qual Life Res; 2004 Sep; 13(7):1209-16. PubMed ID: 15473499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.
    Quinten C; Coens C; Mauer M; Comte S; Sprangers MA; Cleeland C; Osoba D; Bjordal K; Bottomley A;
    Lancet Oncol; 2009 Sep; 10(9):865-71. PubMed ID: 19695956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of changes in health-related quality of life scores during curative treatment for esophagogastric cancer.
    Djärv T; Metcalfe C; Avery KN; Lagergren P; Blazeby JM
    J Clin Oncol; 2010 Apr; 28(10):1666-70. PubMed ID: 20194863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
    Gravis G; Bladou F; Salem N; Macquart-Moulin G; Serment G; Camerlo J; Genre D; Bardou VJ; Maraninchi D; Viens P
    Cancer; 2003 Oct; 98(8):1627-34. PubMed ID: 14534878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-Related Quality of Life Impacts Mortality but Not Progression to End-Stage Renal Disease in Pre-Dialysis Chronic Kidney Disease: A Prospective Observational Study.
    Jesky MD; Dutton M; Dasgupta I; Yadav P; Ng KP; Fenton A; Kyte D; Ferro CJ; Calvert M; Cockwell P; Stringer SJ
    PLoS One; 2016; 11(11):e0165675. PubMed ID: 27832126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of treatment on quality of life of patients with head and neck cancer and its association with prognosis.
    Carrillo JF; Carrillo LC; Ramirez-Ortega MC; Ochoa-Carrillo FJ; Oñate-Ocaña LF
    Eur J Surg Oncol; 2016 Oct; 42(10):1614-21. PubMed ID: 27371998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire.
    Arrieta Ó; Núñez-Valencia C; Reynoso-Erazo L; Alvarado S; Flores-Estrada D; Angulo LP; Oñate-Ocaña LF
    Lung Cancer; 2012 Jul; 77(1):205-11. PubMed ID: 22387006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial.
    Vasarainen H; Lokman U; Ruutu M; Taari K; Rannikko A
    BJU Int; 2012 Jun; 109(11):1614-9. PubMed ID: 22044485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan.
    Inoue T; Segawa T; Kamba T; Yoshimura K; Nakamura E; Nishiyama H; Ito N; Kamoto T; Habuchi T; Ogawa O
    Urology; 2009 May; 73(5):1104-9. PubMed ID: 19394511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study.
    Sánchez-Lara K; Turcott JG; Juárez E; Guevara P; Núñez-Valencia C; Oñate-Ocaña LF; Flores D; Arrieta O
    Nutr Cancer; 2012; 64(4):526-34. PubMed ID: 22489794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients.
    Grande GE; Farquhar MC; Barclay SI; Todd CJ
    Palliat Support Care; 2009 Sep; 7(3):289-97. PubMed ID: 19788770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.
    Wu EQ; Mulani P; Farrell MH; Sleep D
    Value Health; 2007; 10(5):408-14. PubMed ID: 17888106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.